97 related articles for article (PubMed ID: 31765738)
1. Combinational therapeutic targeting of BRD4 and CDK7 synergistically induces anticancer effects in head and neck squamous cell carcinoma.
Zhang W; Ge H; Jiang Y; Huang R; Wu Y; Wang D; Guo S; Li S; Wang Y; Jiang H; Cheng J
Cancer Lett; 2020 Jan; 469():510-523. PubMed ID: 31765738
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of the transcriptional kinase CDK7 overcomes therapeutic resistance in HER2-positive breast cancers.
Sun B; Mason S; Wilson RC; Hazard SE; Wang Y; Fang R; Wang Q; Yeh ES; Yang M; Roberts TM; Zhao JJ; Wang Q
Oncogene; 2020 Jan; 39(1):50-63. PubMed ID: 31462705
[TBL] [Abstract][Full Text] [Related]
3. BRD4 promotes metastatic potential in oral squamous cell carcinoma through the epigenetic regulation of the MMP2 gene.
Yamamoto T; Hirosue A; Nakamoto M; Yoshida R; Sakata J; Matsuoka Y; Kawahara K; Nagao Y; Nagata M; Takahashi N; Hiraki A; Shinohara M; Nakao M; Saitoh N; Nakayama H
Br J Cancer; 2020 Aug; 123(4):580-590. PubMed ID: 32499570
[TBL] [Abstract][Full Text] [Related]
4. Targeting BRD4: Potential therapeutic strategy for head and neck squamous cell carcinoma (Review).
Yongprayoon V; Wattanakul N; Khomate W; Apithanangsiri N; Kasitipradit T; Nantajit D; Tavassoli M
Oncol Rep; 2024 Jun; 51(6):. PubMed ID: 38606512
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer.
Li B; Ni Chonghaile T; Fan Y; Madden SF; Klinger R; O'Connor AE; Walsh L; O'Hurley G; Mallya Udupi G; Joseph J; Tarrant F; Conroy E; Gaber A; Chin SF; Bardwell HA; Provenzano E; Crown J; Dubois T; Linn S; Jirstrom K; Caldas C; O'Connor DP; Gallagher WM
Cancer Res; 2017 Jul; 77(14):3834-3845. PubMed ID: 28455421
[TBL] [Abstract][Full Text] [Related]
6. High MITF Expression Is Associated with Super-Enhancers and Suppressed by CDK7 Inhibition in Melanoma.
Eliades P; Abraham BJ; Ji Z; Miller DM; Christensen CL; Kwiatkowski N; Kumar R; Njauw CN; Taylor M; Miao B; Zhang T; Wong KK; Gray NS; Young RA; Tsao H
J Invest Dermatol; 2018 Jul; 138(7):1582-1590. PubMed ID: 29408204
[TBL] [Abstract][Full Text] [Related]
7. BET inhibitor nanotherapy halts kidney damage and reduces chronic kidney disease progression after ischemia-reperfusion injury.
Saiz ML; Lozano-Chamizo L; Florez AB; Marciello M; Diaz-Bulnes P; Corte-Iglesias V; Bernet CR; Rodrigues-Diez RR; Martin-Martin C; Rodriguez-Santamaria M; Fernandez-Vega I; Rodriguez RM; Diaz-Corte C; Suarez-Alvarez B; Filice M; Lopez-Larrea C
Biomed Pharmacother; 2024 May; 174():116492. PubMed ID: 38537579
[TBL] [Abstract][Full Text] [Related]
8. BRD4 as a therapeutic target for nonfunctioning and growth hormone pituitary adenoma.
Shi C; Ye Z; Han J; Ye X; Lu W; Ji C; Li Z; Ma Z; Zhang Q; Zhang Y; He W; Chen Z; Cao X; Shou X; Zhou X; Wang Y; Zhang Z; Li Y; Ye H; He M; Chen H; Cheng H; Sun J; Cai J; Huang C; Ye F; Luo C; Zhou B; Ding H; Zhao Y
Neuro Oncol; 2020 Aug; 22(8):1114-1125. PubMed ID: 32246150
[TBL] [Abstract][Full Text] [Related]
9. Peptide Inhibitor Targeting the Extraterminal Domain in BRD4 Potently Suppresses Breast Cancer Both
Huang QX; Fan DM; Zheng ZZ; Ran T; Bai A; Xiao RQ; Hu GS; Liu W
J Med Chem; 2024 Apr; 67(8):6658-6672. PubMed ID: 38569135
[TBL] [Abstract][Full Text] [Related]
10. PROTAC Prodrug-Integrated Nanosensitizer for Potentiating Radiation Therapy of Cancer.
Zhang S; Lai Y; Pan J; Saeed M; Li S; Zhou H; Jiang X; Gao J; Zhu Y; Yu H; Zhang W; Xu Z
Adv Mater; 2024 Jun; 36(23):e2314132. PubMed ID: 38353332
[TBL] [Abstract][Full Text] [Related]
11. CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma.
Yao Y; Ng JF; Park WD; Samur M; Morelli E; Encinas Mayoral J; Chyra Z; Xu Y; Derebail S; Epstein C; Nabet B; Chesi M; Gray NS; Young RA; Kwiatkowski N; Mitsiades C; Anderson KC; Lin CY; Munshi NC; Fulciniti M
Blood; 2023 Jun; 141(23):2841-2852. PubMed ID: 36877894
[TBL] [Abstract][Full Text] [Related]
12. Brd4 inhibition ameliorates Pyocyanin-mediated macrophage dysfunction via transcriptional repression of reactive oxygen and nitrogen free radical pathways.
Zhu F; Xiong F; He J; Liu K; You Y; Xu Q; Miao J; Du Y; Zhang L; Ren H; Wang X; Chen J; Li J; Chen S; Liu X; Huang N; Wang Y
Cell Death Dis; 2020 Jun; 11(6):459. PubMed ID: 32541671
[TBL] [Abstract][Full Text] [Related]
13. CDK7 in breast cancer: mechanisms of action and therapeutic potential.
Gong Y; Li H
Cell Commun Signal; 2024 Apr; 22(1):226. PubMed ID: 38605321
[TBL] [Abstract][Full Text] [Related]
14. Identification of CDK7 Inhibitors from Natural Sources Using Pharmacoinformatics and Molecular Dynamics Simulations.
Kumar V; Parate S; Thakur G; Lee G; Ro HS; Kim Y; Kim HJ; Kim MO; Lee KW
Biomedicines; 2021 Sep; 9(9):. PubMed ID: 34572383
[TBL] [Abstract][Full Text] [Related]
15. Suppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression.
Rusan M; Li K; Li Y; Christensen CL; Abraham BJ; Kwiatkowski N; Buczkowski KA; Bockorny B; Chen T; Li S; Rhee K; Zhang H; Chen W; Terai H; Tavares T; Leggett AL; Li T; Wang Y; Zhang T; Kim TJ; Hong SH; Poudel-Neupane N; Silkes M; Mudianto T; Tan L; Shimamura T; Meyerson M; Bass AJ; Watanabe H; Gray NS; Young RA; Wong KK; Hammerman PS
Cancer Discov; 2018 Jan; 8(1):59-73. PubMed ID: 29054992
[TBL] [Abstract][Full Text] [Related]
16. Selective inhibition of CDK7 reveals high-confidence targets and new models for TFIIH function in transcription.
Rimel JK; Poss ZC; Erickson B; Maas ZL; Ebmeier CC; Johnson JL; Decker TM; Yaron TM; Bradley MJ; Hamman KB; Hu S; Malojcic G; Marineau JJ; White PW; Brault M; Tao L; DeRoy P; Clavette C; Nayak S; Damon LJ; Kaltheuner IH; Bunch H; Cantley LC; Geyer M; Iwasa J; Dowell RD; Bentley DL; Old WM; Taatjes DJ
Genes Dev; 2020 Nov; 34(21-22):1452-1473. PubMed ID: 33060135
[TBL] [Abstract][Full Text] [Related]
17. Targeting Super-Enhancers via Nanoparticle-Facilitated BRD4 and CDK7 Inhibitors Synergistically Suppresses Pancreatic Ductal Adenocarcinoma.
Huang CS; You X; Dai C; Xu QC; Li F; Wang L; Huang XT; Wang JQ; Li SJ; Gao Z; Wu J; Yin XY; Zhao W
Adv Sci (Weinh); 2020 Apr; 7(7):1902926. PubMed ID: 32274304
[TBL] [Abstract][Full Text] [Related]
18. CDK7 Inhibition is Effective in all the Subtypes of Breast Cancer: Determinants of Response and Synergy with EGFR Inhibition.
McDermott MSJ; Sharko AC; Munie J; Kassler S; Melendez T; Lim CU; Broude EV
Cells; 2020 Mar; 9(3):. PubMed ID: 32155786
[TBL] [Abstract][Full Text] [Related]
19. CDK7 Inhibition Potentiates Genome Instability Triggering Anti-tumor Immunity in Small Cell Lung Cancer.
Zhang H; Christensen CL; Dries R; Oser MG; Deng J; Diskin B; Li F; Pan Y; Zhang X; Yin Y; Papadopoulos E; Pyon V; Thakurdin C; Kwiatkowski N; Jani K; Rabin AR; Castro DM; Chen T; Silver H; Huang Q; Bulatovic M; Dowling CM; Sundberg B; Leggett A; Ranieri M; Han H; Li S; Yang A; Labbe KE; Almonte C; Sviderskiy VO; Quinn M; Donaghue J; Wang ES; Zhang T; He Z; Velcheti V; Hammerman PS; Freeman GJ; Bonneau R; Kaelin WG; Sutherland KD; Kersbergen A; Aguirre AJ; Yuan GC; Rothenberg E; Miller G; Gray NS; Wong KK
Cancer Cell; 2020 Jan; 37(1):37-54.e9. PubMed ID: 31883968
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
